CA2087510A1 - Method of using m1-selective antimuscarinic pyridobenzodiazepiones in axial myopia therapy - Google Patents

Method of using m1-selective antimuscarinic pyridobenzodiazepiones in axial myopia therapy

Info

Publication number
CA2087510A1
CA2087510A1 CA002087510A CA2087510A CA2087510A1 CA 2087510 A1 CA2087510 A1 CA 2087510A1 CA 002087510 A CA002087510 A CA 002087510A CA 2087510 A CA2087510 A CA 2087510A CA 2087510 A1 CA2087510 A1 CA 2087510A1
Authority
CA
Canada
Prior art keywords
animal
myopia
eye
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002087510A
Other languages
English (en)
French (fr)
Inventor
Pierre Mallorga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CA2087510A1 publication Critical patent/CA2087510A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002087510A 1992-01-21 1993-01-18 Method of using m1-selective antimuscarinic pyridobenzodiazepiones in axial myopia therapy Abandoned CA2087510A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82349592A 1992-01-21 1992-01-21
US823,495 1992-01-21

Publications (1)

Publication Number Publication Date
CA2087510A1 true CA2087510A1 (en) 1993-07-22

Family

ID=25238929

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002087510A Abandoned CA2087510A1 (en) 1992-01-21 1993-01-18 Method of using m1-selective antimuscarinic pyridobenzodiazepiones in axial myopia therapy

Country Status (10)

Country Link
EP (1) EP0556947A1 (en:Method)
JP (1) JPH0742231B2 (en:Method)
CN (1) CN1074606A (en:Method)
AU (1) AU3192393A (en:Method)
CA (1) CA2087510A1 (en:Method)
IL (1) IL104409A0 (en:Method)
MX (1) MX9300250A (en:Method)
TW (1) TW222583B (en:Method)
WO (1) WO1993013777A1 (en:Method)
ZA (2) ZA93384B (en:Method)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
WO1998030900A2 (en) * 1997-01-06 1998-07-16 Klaus Trier Aps Screening method for compounds active in treating myopia and hypermetropia
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
JP6784407B2 (ja) * 2015-04-24 2020-11-11 学校法人慶應義塾 近視予防剤及び近視進行抑制剤
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US10845622B2 (en) 2015-09-15 2020-11-24 Largan Medical Co., Ltd. Multifocal contact lens and contact lens product
US12298602B2 (en) 2015-09-15 2025-05-13 Largan Medical Co., Ltd. Multifocal contact lens and contact lens product
CN110308571B (zh) 2015-09-15 2024-01-30 星欧光学股份有限公司 隐形眼镜产品
CN115414357B (zh) * 2022-08-30 2023-09-22 天津医科大学眼科医院 一种酰胺类化合物在制备防治近视的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (it) * 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
WO1990015604A1 (en) * 1989-06-21 1990-12-27 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development

Also Published As

Publication number Publication date
TW222583B (en:Method) 1994-04-21
IL104409A0 (en) 1993-05-13
ZA93384B (en) 1993-08-23
EP0556947A1 (en) 1993-08-25
ZA93374B (en) 1993-08-23
JPH0742231B2 (ja) 1995-05-10
AU3192393A (en) 1993-07-22
CN1074606A (zh) 1993-07-28
WO1993013777A1 (en) 1993-07-22
MX9300250A (es) 1993-07-01
JPH06206820A (ja) 1994-07-26

Similar Documents

Publication Publication Date Title
EP0737475B1 (en) Use of a muscarinic antagonist in the manufacture of a medicament for the treatment and control of ocular development
CA2087510A1 (en) Method of using m1-selective antimuscarinic pyridobenzodiazepiones in axial myopia therapy
JP2022523332A (ja) 近視を治療するための化合物、組成物及び方法
CA2058768C (en) Treatment and control of ocular development
JPH078805B2 (ja) 眼の発育の神経ペプチド制御
CN111349036B (zh) 一种格隆溴铵的替代物及其制备方法和医药用途
AU677860B2 (en) Composition for prophylaxis and treatment of myopia
US5952338A (en) Agent for prophylaxis and treatment of disturbance of visual function
JP3066561B2 (ja) 近視予防・治療剤
McCLANAHAN et al. Ocular manifestations of chronic phenothiazine derivative administration
CA2270119A1 (en) Drugs for ameliorating ocular circulatory disorders
US5461052A (en) Prevention of myopia by tricyclic compounds
JPH10203982A (ja) 視機能障害の予防・治療剤
KR19990080875A (ko) 갈라민을 유효성분으로 하는 근시예방 및 치료용 조성물
CA2369054C (en) Treatment and control of ocular development
KR20000013487A (ko) 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물
HK1007681B (en) Use of pirenzepine, telenzepine oder o-methoxy-sila-hexocyclium in the manufacture of a medicament for the treatment and control of ocular development
WO1993005777A1 (fr) Preparation transoculaire
CA2346086A1 (en) Composition for treatment of light-injured retinal degeneration disease
EP0606393A1 (en) Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use

Legal Events

Date Code Title Description
FZDE Discontinued